CHESTNUT RIDGE, N.Y., Nov. 19, 2020 /PRNewswire/ -- BioHiTech Global, Inc. ("BioHiTech" or the "Company") BHTG, a sustainable technology and services company, today announces financial results for its third quarter 2020 ended September 30, 2020.
Third Quarter Highlights:
- Announced that Carnival Corp., the world's largest cruise company, reinitiated its installation program of the BioHiTech's Revolution Series Digesters aboard its ships in preparation for the eventual resumption of cruising
- Announced a total of $1.4 million in new food waste digester purchase orders for its Revolution Series Digesters from Carnival Corp. as part of its previously announced purchase contract between the two companies with an estimated value of up to $14 million
- Received first Altapure AP-4™ disinfectant systems purchase contract from Hazelton Area School District in Pennsylvania to protect its schools against COVID-19 and other viral infections
- Shipped the first Altapure AP-4™ disinfectant system to the cruise industry where it will be installed on the SeaDream I yacht, a mega-yacht boutique ship
- Closed an $9.5 million (gross) underwritten public offering, including the underwriter's over-allotment, with net proceeds of $8.4 million to the Company
Developments Subsequent to the End of the Third Quarter
- Appointed Anthony Fuller as Chief Executive Officer
- Received contract to install seven new food waste digesters at various Hackensack Meridian Health healthcare facility locations
- Made strategic investment in Rensselaer, NY land venture as a material step to establishing a renewable energy campus, including New York state's first waste conversion facility
- Announced a total of $1.9 million in new food waste digester purchases, bringing total orders received from Carnival Corp. for the Company's Revolution Series™ food waste digesters to $3.3 million, including $600,000 in digester orders from Princess Cruises, since Carnival reinitiated the installation of digesters on its ships in July 2020
"While the third quarter fell short of our expectations financially, a number of significant events during the quarter and after September 30 provide reasons to believe better quarters are ahead," commented BioHiTech's CEO Anthony Fuller. "Carnival Corp. has placed $3.3 million worth of food waste digesters orders since July, providing what we believe is an incredible testimony to our technology and ability to solve real-world food waste problems for the travel and hospitality industry. Additionally, our multi-unit order for food digesters from the Hackensack Meridian Healthcare system provides further validation for our Revolution Series Digesters that convert food waste into a liquid that can be safely discharged through any standard sewer line.
"The Altapure AP-4 disinfectant system saw initial deployments in a school district as well as on a cruise ship, and we are confident it can address future needs across a range of industries, all of which have been affected by COVID-19. We continue to ascend the learning curve of operating our Martinsburg, W.V. plant using our patented High Efficiency Biological Treatment ("HEBioT") process. In many ways, are still in the commissioning phase with this plant. We've made notable changes and are pleased with the progress we are seeing. Our learnings from the Martinsburg facility will prove vital as we progress towards our potential development of a 'renewable energy campus' planned for Rensselaer, N.Y. Quite simply, BioHiTech provides cost-effective technology solutions for sustainable waste management, whether on a large scale like our Martinsburg resource recovery facility or on a smaller scale via our food waste digesters.
"As we look ahead to 2021 and beyond, and as the newly appointed CEO, we are setting course with enhanced corporate initiatives. These initiatives are designed to maximize shareholder value and help investors better measure our progress moving forward. I've laid out five goals on which we are focused heading into 2021: 1) increase revenue appreciably, 2) reduce SG&A meaningfully, 3) improve the plant operations measurably, 4) tell the story clearly, and 5) function as a team effectively. I look forward to elaborating more on these goals in our earnings conference call later this afternoon and throughout the quarter," concluded Mr. Fuller.
Financial Highlights for Q3 2020
Revenues: Total revenue in the third quarter of 2020 was $742,877, a decrease of 48% compared to revenue of $1,426,775 in the third quarter of 2019. Third quarter revenue decreased primarily due to a reconfiguration process conducted at the Martinsburg (W.V.) High Efficiency Biological Treatment (HEBioT) facility during the quarter by the facility's new management team that temporarily reduced production and caused its revenue to decline by 59% year-over-year to $248,274 prior to a $247,649 negative adjustment in previously estimated take-or-pay contract revenue. Rental, service, and maintenance revenue declined 13% from $489,555 in the third quarter of 2019 to $423,996 in the third quarter of 2020. Equipment sales partially offset the declines in the HEBioT and rental, service, and maintenance revenue and rose 370% from $62,565 in the third quarter of 2019 to $293,876 in the third quarter of 2020 due to purchases from Carnival Cruise Lines under their master purchase contract. Furthermore, management advisory and other fees derived support for Gold Medal, a related entity, decreased from $264,750 in the third quarter of 2019 to $24,380 in the third quarter of 2020 in order for management to devote more focus to the Company's core services.
Operating Expenses: Total Operating Expenses, including $1,256,477 in cost of goods sold and a $917,420 impairment expense at the Martinsburg waste facility, in the third quarter increased 53% from $3,042,020 in the third quarter of 2019 to $4,660,333 in the third quarter of 2020. Increased production expenses, the aforementioned impairment expense, stock-based compensation, legal and social media expenses, insurance costs at the HEBioT facility, Directors and Officers insurance, and management transition expenses at the HEBioT facility primarily drove the increased operating expenses from the comparable period in 2019.
Loss from Operations: The loss from operations increased from ($1,615,245) in the third quarter of 2019 to a loss of ($3,917,456) in the third quarter of 2020.
Net Loss: Net loss per share in the third quarter of 2020 was ($0.16) on 22.0 million weighted average shares outstanding, compared to a net loss of ($0.13) per share on 15.6 million weighted average shares outstanding in third quarter of 2019.
Cash: Unrestricted cash at September 30, 2020 was $4,950,112 following an underwritten public offering completed during the third quarter that netted the Company $8,437,480 in proceeds, including the underwriter's over-allotment.
Earnings Conference Call
Management will host a conference call at 4:30 p.m. ET on Thursday, November 19, 2020 to review financial results and provide an update on corporate developments. Following management's formal remarks, there will be a question and answer session.
Participants are asked to pre-register for the call via the following link:
https://dpregister.com/sreg/10150010/dd340fff34
Please note that registered participants will receive their dial-in number upon registration and will dial directly into the call without delay. Those without Internet access or who are unable to pre-register may dial in by calling 1-866-652-5200 (domestic) or 1-412-317-6060 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the BioHiTech Global call.
The conference call will be available through a live webcast found here:
https://services.choruscall.com/links/bhtg201116.html
It will also be broadcast live through the Company's website with the following link:
http://investors.biohitechglobal.com/events-and-webcasts
A webcast replay of the call can be accessed through the above links and will be available approximately one hour after the end of the call through February 19, 2021. The call replay can also be accessed by calling 1-877-344-7529 (domestic) or 1-412-317-0088 (international) and using access code 10150010. The telephonic replay of the call will be available through November 30, 2020.
About BioHiTech Global
BioHiTech Global, Inc. BHTG, is a technology services company focused on providing cost-effective solutions that improve environmental outcomes. Our technologies for waste management include the patented processing of municipal solid waste into a valuable renewable fuel, biological disposal of food waste on-site, and proprietary real-time data analytics tools to reduce food waste generation. When used individually or in combination, our solutions lower the carbon footprint associated with waste transportation and can reduce or virtually eliminate landfill usage. In addition, we distribute a patented technology that achieves high-level disinfection of spaces such as classrooms, hotel or hospital rooms and other enclosed areas to combat the spread of viruses and bacteria without the use of harsh chemicals. Our unique solutions enable businesses, educational institutions and municipalities of all sizes to solve everyday problems in a smarter and more cost-effective way while reducing their impact on the environment. For more information, please visit www.biohitech.com.
Forward Looking Statements
Statements in this press release contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. Without limiting the foregoing, words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "explore," "evaluate," "intend," "may," "might," "plan," "potential," "predict," "project," "seek," "should," or "will," or the negative thereof or other variations thereon or comparable terminology. These forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These statements are also based on many assumptions and estimates and are not guarantees of future performance. These statements are estimates, based on information available to management as of the date of this release, and are subject to further changes. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of BioHiTech Global, Inc. to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. BioHiTech Global, Inc. assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future in these forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission ("SEC"). There may be other factors not mentioned above or included in the BioHiTech's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. BioHiTech Global, Inc. assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
Company Contact:
BioHiTech Global, Inc.
Richard Galterio
Executive Vice President
Direct: 845.367.0603
rgalterio@biohitech.com
www.biohitech.com
Investors:
ir@biohitech.com
BioHiTech Global, Inc. and Subsidiaries | ||||||||||||||||
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) | ||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
2020 | 2019 | 2020 | 2019 | |||||||||||||
Revenue | ||||||||||||||||
HEBioT (related party) | $ | 625 | $ | 609,905 | $ | 1,383,656 | $ | 886,947 | ||||||||
Rental, service and maintenance | 423,996 | 489,555 | 1,251,122 | 1,426,193 | ||||||||||||
Equipment sales | 293,876 | 62,565 | 616,992 | 137,799 | ||||||||||||
Management advisory and other fees | 24,380 | 264,750 | 124,380 | 761,750 | ||||||||||||
Total revenue | 742,877 | 1,426,775 | 3,376,150 | 3,212,689 | ||||||||||||
Operating expenses | ||||||||||||||||
HEBioT processing | 945,810 | 786,680 | 2,778,514 | 1,309,176 | ||||||||||||
Rental, service and maintenance | 139,665 | 176,651 | 552,195 | 508,164 | ||||||||||||
Equipment sales | 171,002 | 17,776 | 317,406 | 56,502 | ||||||||||||
Selling, general and administrative | 1,924,293 | 1,449,545 | 5,740,158 | 5,450,282 | ||||||||||||
Impairment expense | 917,420 | - | 917,420 | - | ||||||||||||
Depreciation and amortization | 562,143 | 611,368 | 1,747,109 | 1,350,780 | ||||||||||||
Total operating expenses | 4,660,333 | 3,042,020 | 12,052,802 | 8,674,904 | ||||||||||||
Loss from operations | (3,917,456) | (1,615,245) | (8,676,652) | (5,462,215) | ||||||||||||
Other (income) expenses | ||||||||||||||||
Gain on sale of affiliate investment | - | (562,617) | - | (562,617) | ||||||||||||
Interest (income) | (108) | (46,180) | (17,730) | (46,180) | ||||||||||||
Interest expense | 1,023,165 | 979,202 | 3,060,775 | 2,281,071 | ||||||||||||
Expense incurred in warrant valuation | - | 49,160 | - | 49,160 | ||||||||||||
Total other (income) expenses | 1,023,057 | 419,565 | 3,043,045 | 1,721,434 | ||||||||||||
Net loss | (4,940,513) | (2,034,810) | (11,719,697) | (7,183,649) | ||||||||||||
Net loss attributable to non-controlling | (1,647,782) | (728,337) | (3,190,788) | (1,859,069) | ||||||||||||
Net loss attributable to Parent | (3,292,731) | (1,306,473) | (8,528,909) | (5,324,580) | ||||||||||||
Other comprehensive income | ||||||||||||||||
Foreign currency translation adjustment | 71,067 | (32,676) | 40,931 | (37,873) | ||||||||||||
Comprehensive loss | $ | (3,221,664) | $ | (1,339,149) | $ | (8,487,978) | $ | (5,362,453) | ||||||||
Net loss attributable to Parent | $ | (3,292,731) | $ | (1,306,473) | $ | (8,528,909) | $ | (5,324,580) | ||||||||
Preferred stock dividends | (205,115) | (255,847) | (587,428) | (548,075) | ||||||||||||
Deemed dividend on down round | (21,738) | (405,324) | (21,738) | (405,324) | ||||||||||||
Net loss – common shareholders | (3,519,584) | (1,967,644) | (9,138,075) | (6,277,979) | ||||||||||||
Net loss per common share - basic and | $ | (0.16) | $ | (0.13) | $ | (0.49) | $ | (0.41) | ||||||||
Weighted average number of common | 22,044,540 | 15,649,174 | 18,787,566 | 15,134,301 | ||||||||||||
BioHiTech Global, Inc. and Subsidiaries | ||||||||
Condensed Consolidated Balance Sheets | ||||||||
September 30, | December 31, | |||||||
(Unaudited) | ||||||||
Assets | ||||||||
Current Assets | ||||||||
Cash | $ | 4,950,112 | $ | 1,847,526 | ||||
Restricted cash | 1,287,138 | 1,133,581 | ||||||
Accounts receivable, net of allowance for doubtful accounts of $194,066 and $170,038 | 3,311,519 | 2,155,921 | ||||||
Inventory | 627,261 | 467,784 | ||||||
Prepaid expenses and other current assets | 240,939 | 126,357 | ||||||
Total Current Assets | 10,416,969 | 5,731,169 | ||||||
Restricted cash | 2,646,448 | 2,555,845 | ||||||
Equipment on operating leases, net | 1,417,260 | 1,724,998 | ||||||
HEBioT facility, equipment, fixtures and vehicles, net | 36,338,727 | 37,421,333 | ||||||
Operating lease right of use assets | 1,285,292 | 945,047 | ||||||
License and capitalized MBT facility development costs | 8,018,853 | 8,049,929 | ||||||
Goodwill | 58,000 | 58,000 | ||||||
Other assets | 33,749 | 53,726 | ||||||
Total Assets | $ | 60,215,298 | $ | 56,540,047 | ||||
Continued on following page. | ||||||||
BioHiTech Global, Inc. and Subsidiaries | ||||||||
Condensed Consolidated Balance Sheets, continued: | ||||||||
September 30, | December 31, | |||||||
(Unaudited) | ||||||||
Liabilities and Stockholders' Equity | ||||||||
Current Liabilities: | ||||||||
Line of credit, net of financing costs of $2,050 and $20,152 as of September 30, 2020 | $ | 1,497,950 | $ | 1,479,848 | ||||
Advances from related parties | 935,000 | 210,000 | ||||||
Accounts payable (related entity $2,021,940 and $2,531,034 as of September 30, 2020 | 6,363,168 | 4,688,339 | ||||||
Accrued interest payable | 627,112 | 1,148,570 | ||||||
Accrued expenses and liabilities | 2,075,576 | 1,926,965 | ||||||
Deferred revenue | 95,331 | 89,736 | ||||||
Customer deposits | 753,046 | 44,792 | ||||||
Note payable | - | 100,000 | ||||||
Senior Secured Note, net of financing costs of $75,767 and unamortized discounts of | 4,408,514 | - | ||||||
Current portion of WV EDA Senior Secured Bonds payable | 2,860,000 | 1,390,000 | ||||||
Current portion of long term debt and Payroll Protection Program Loan | 261,787 | 4,605 | ||||||
Total Current Liabilities | 19,877,484 | 11,082,855 | ||||||
Junior note due to related party, net of unamortized discounts of $78,596 and $95,043 | 965,881 | 949,434 | ||||||
Accrued interest (related party) | 1,729,605 | 1,510,193 | ||||||
WV EDA Senior Secured Bonds payable, net of current portion, and financing costs of | 28,448,484 | 29,817,426 | ||||||
Payroll Protection Program Loan, net of current portion | 163,839 | - | ||||||
Senior Secured Note, net of current portion, net of financing costs of $113,268, and | - | 4,160,490 | ||||||
Note Payable | 100,000 | - | ||||||
Non-current lease liabilities | 1,231,144 | 915,170 | ||||||
Long-term debt, net of current portion | 4,936 | 8,201 | ||||||
Total Liabilities | 52,521,373 | 48,443,769 | ||||||
Series A redeemable convertible preferred stock, 333,401 shares designated and issued, | 626,553 | 726,553 | ||||||
Commitments and Contingencies | ||||||||
Stockholders' Equity | ||||||||
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; 3,209,210 and | ||||||||
Series B Convertible preferred stock, 1,111,200 shares designated: 428,333 shares | - | - | ||||||
Series C Convertible preferred stock, 1,000,000 shares designated, 427,500 shares | 3,050,142 | 3,050,142 | ||||||
Series D Convertible preferred stock, 20,000 shares designated: 18,850 shares | 1,365,696 | 1,505,262 | ||||||
Series E Convertible preferred stock, 714,519 shares designated: 714,519 shares | 698,330 | 698,330 | ||||||
Series F Convertible preferred stock, 30,090 shares designated, and 13,611 shares | 1,507,408 | - | ||||||
Common stock, $0.0001 par value, 50,000,000 shares authorized, 23,354,130 and | 2,334 | 1,730 | ||||||
Additional paid in capital | 59,775,963 | 49,597,059 | ||||||
Accumulated deficit | (61,403,226) | (52,785,242) | ||||||
Accumulated other comprehensive (loss) | (84,069) | (43,138) | ||||||
Stockholders' equity attributable to Parent | 4,912,578 | 2,024,143 | ||||||
Stockholders' equity attributable to non-controlling interests | 2,154,794 | 5,345,582 | ||||||
Total Stockholders' Equity | 7,067,372 | 7,369,725 | ||||||
Total Liabilities and Stockholders' Equity | $ | 60,215,298 | $ | 56,540,047 | ||||
BioHiTech Global, Inc. and Subsidiaries | ||||||||
Condensed Consolidated Statements of Cash Flows (Unaudited) | ||||||||
Nine Months Ended | ||||||||
2020 | 2019 | |||||||
Cash flows from operating activities: | ||||||||
Net loss | $ | (11,719,697) | (7,183,649) | |||||
Adjustments to reconcile net loss to net cash used in operations: | ||||||||
Depreciation and amortization | 1,747,109 | 1,350,780 | ||||||
Impairment expense | 917,420 | - | ||||||
Amortization of operating lease right of use assets | 72,402 | - | ||||||
Provision for bad debts | 126,119 | 45,000 | ||||||
Share based employee compensation | 1,537,915 | 741,188 | ||||||
Interest resulting from amortization of financing costs and discounts | 419,715 | 333,782 | ||||||
Share based vendor compensation | 297,835 | - | ||||||
Gain on sale of affiliate investment | - | (562,617) | ||||||
Loss resulting from write-off of proposed MBT site | - | 346,654 | ||||||
Warrant modifications | - | 49,160 | ||||||
Changes in operating assets and liabilities | (909,507) | (1,137,810) | ||||||
Net cash used in operating activities | (7,510,689) | (6,017,512) | ||||||
Cash flow from investing activities: | ||||||||
Purchases of construction in-progress, equipment, fixtures and vehicles | (207,173) | (4,619,883) | ||||||
Proceeds from sale of investment in affiliate | - | 2,250,000 | ||||||
Refund of deposit | 5,000 | - | ||||||
MBT facility development costs incurred | (62,949) | (59,013) | ||||||
MBT facility development costs refunded | - | 66,000 | ||||||
Net cash used in investing activities | (265,122) | (2,362,896) | ||||||
Cash flows from financing activities: | ||||||||
Proceeds from common stock issuance, net of offering costs | 8,437,480 | 3,035,557 | ||||||
Proceeds from the sale of Series F convertible preferred stock units | 1,560,450 | - | ||||||
Proceeds from Payroll Protection Program Loan | 421,300 | - | ||||||
Proceeds from the sale of Series D convertible preferred stock units | - | 1,772,500 | ||||||
Affiliate investment in subsidiary | - | 1,400,000 | ||||||
Deferred financing costs incurred | - | (62,151) | ||||||
Repayments of long-term debt | (3,544) | (6,846) | ||||||
Related party advances, net | 725,000 | 210,000 | ||||||
Net cash provided by financing activities | 11,140,686 | 6,349,060 | ||||||
Effect of exchange rate on cash (restricted and unrestricted) | (18,129) | 12,721 | ||||||
Net change in cash (restricted and unrestricted) | 3,346,746 | (2,018,627) | ||||||
Cash - beginning of period (restricted and unrestricted) | 5,536,952 | 9,126,380 | ||||||
Cash - end of period (restricted and unrestricted) | $ | 8,883,698 | 7,107,753 | |||||
View original content to download multimedia:http://www.prnewswire.com/news-releases/biohitech-global-reports-third-quarter-2020-financial-results-301177585.html
SOURCE BioHiTech Global, Inc.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
